Monash IVF Group Osake

Monash IVF Group EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Monash IVF Group (MVF.AX) 6.8.2026 päivämäärällä on 66,19 M AUD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 12,97 M AUD — muutos 410,39 % (korkeampi).

EBITDA

66,19 MAUD

YoY

410,39%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Monash IVF Group on 2026 66,19 M AUD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Monash IVF Group oli 2025 12,97 M AUD. Se laskee 410,39% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Monash IVF Group Osakeanalyysi

Mitä Monash IVF Group tekee? The Monash IVF Group Ltd is a company in Australia specializing in reproductive medicine. It was founded in 1970 by Professor Gab Kovacs, who is considered one of the pioneers in the field of in-vitro fertilization (IVF). The company's history began in a small laboratory in Melbourne, where the first successful IVF procedures were performed. Over time, Monash IVF grew and expanded its focus to include other reproductive treatments such as donor egg programs, sperm donation, and cryopreservation. Monash IVF Group Ltd has since become a leading provider in Australia, with 19 clinics throughout the country. The company is not only active in Australia but also operates clinics in Malaysia and Vietnam. The business model of Monash IVF Group Ltd is centered around helping couples and individuals fulfill their desire to have children. The company offers a wide range of treatments tailored to the individual needs and circumstances of each patient. Among the services offered are not only IVF, donor egg programs, and sperm donation but also other technologies such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD). Monash IVF Group Ltd sees itself as an all-rounder and therefore also offers psychological support and guidance during and after treatments. One of the company's specialties is its comprehensive research work. The Monash IVF Group has a specialized research department actively involved in researching new reproductive technologies. The company collaborates closely with universities and leading scientific institutes to gain the latest insights in this field and achieve the best possible outcomes for its patients. Monash IVF Group Ltd is divided into various divisions, each with different focuses and offerings. The main division is the Monash IVF Clinic, specializing in reproductive health and fertility. Here, all common IVF and fertility treatments are offered. Another division is Monash IVF Fertility Diagnostics, specializing in diagnostics and screening of fertility and reproductive problems. State-of-the-art diagnostic procedures for evaluating male and female fertility are used here. Monash IVF Genomics is another division offering genetic counseling, screening, and diagnostics. Here, couples can determine their genetic risk factors for fertility problems and receive support in making the best possible decisions regarding family planning. In addition to these divisions, Monash IVF Group Ltd also offers specialized services. For example, there is the Monash IVF Donor Program, specializing in the facilitation of anonymous and open donor programs. The Monash IVF DNA Matching can also assist in the search for genetic relatives by utilizing advanced DNA profiling. As a leading company in the field of fertility, Monash IVF Group Ltd offers a wide range of products and services to help couples and individuals fulfill their desire to have children. With a long history of innovation and research, as well as a variety of divisions and offerings, the company is an important provider of reproductive medicine in Australia and beyond. Monash IVF Group on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Monash IVF Group osakkeesta

Yhtiön Monash IVF Group EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 66,19 M AUD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Monash IVF Group muuttui arvosta 12,97 M AUD arvoon 66,19 M AUD, mikä edustaa 410,39 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Monash IVF Group:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n AUD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Monash IVF Group historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Monash IVF Group

Kaikki tunnusluvut — Monash IVF Group